1. Home
  2. TPG vs GKOS Comparison

TPG vs GKOS Comparison

Compare TPG & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TPG Inc.

TPG

TPG Inc.

HOLD

Current Price

$43.01

Market Cap

7.0B

Sector

Finance

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$126.81

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPG
GKOS
Founded
1992
1998
Country
United States
United States
Employees
1900
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
TPG
GKOS
Price
$43.01
$126.81
Analyst Decision
Buy
Strong Buy
Analyst Count
15
12
Target Price
$61.20
$126.92
AVG Volume (30 Days)
2.0M
1.3M
Earning Date
05-01-2026
04-29-2026
Dividend Yield
4.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
N/A
$23.32
Revenue Next Year
$19.79
$27.43
P/E Ratio
$106.82
N/A
Revenue Growth
N/A
32.33
52 Week Low
$36.95
$73.16
52 Week High
$70.38
$148.11

Technical Indicators

Market Signals
Indicator
TPG
GKOS
Relative Strength Index (RSI) 54.60 53.33
Support Level $38.68 $94.16
Resistance Level $46.14 $147.43
Average True Range (ATR) 1.66 7.18
MACD 0.16 1.01
Stochastic Oscillator 72.40 91.26

Price Performance

Historical Comparison
TPG
GKOS

About TPG TPG Inc.

TPG Inc is an alternative asset management firm. It invests across five multi-product platforms, namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, market solutions, innovation, and inclusion.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: